title: Transforming growth factor beta 1 (TGF-beta1) and rapamycin synergize to effectively suppress human T cell responses via upregulation of FoxP3+ Tregs.
authors.affiliation: Department of Surgery, Schulze Diabetes Institute, University of Minnesota, Minneapolis, United States.
authors.forename: Koichi
authors.initials: K
authors.lastname: Kawamoto
authors.forename: Anil
authors.initials: A
authors.lastname: Pahuja
authors.forename: Bernhard J
authors.initials: BJ
authors.lastname: Hering
authors.forename: Pratima
authors.initials: P
authors.lastname: Bansal-Pakala
mesh_terms: D002454:Cell Differentiation / Q000187:drug effects; D004357:Drug Synergism; D051858:Forkhead Transcription Factors / Q000378:metabolism*; D006801:Humans; D020123:Sirolimus / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000166:cytology / Q000187:drug effects* / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects; D053773:Transforming Growth Factor beta1 / Q000494:pharmacology*; D015854:Up-Regulation / Q000187:drug effects*
chemical_list: C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors; D053773:Transforming Growth Factor beta1; D020123:Sirolimus